|Bid||17.09 x 1400|
|Ask||17.10 x 800|
|Day's Range||16.65 - 17.23|
|52 Week Range||7.15 - 20.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.29|
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Array BioPharma Inc. (NASDAQ: ARRY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARRY as the Company's latest news hit the wire. On July 13, 2018, the Company, which is a fully-integrated, biopharmaceutical Company, declared that the National Comprehensive Cancer Network (NCCN) has revised the Clinical Practice Guidelines in Oncology for Melanoma. The new guidelines make BRAFTOVI™ in combination with MEKTOVI® a Category 1 first-line and second-line treatment option for patients suffering with BRAFV600E, or BRAFV600K-mutant metastatic, or unresectable melanoma.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $1.26 billion.
BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in ...
Yesterday, Array Biopharma announced that it received FDA approval for its combination therapy for advanced melanoma associated with a common gene mutation called a BRAF mutation. This is the first marketable regimen for Array Biopharma and is labeled as the first-line therapy.
The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY )’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. The stock, which rallied ...
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 ...
The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer. The combination therapy, which consists of encorafenib and binimetinib, was approved based on the company's late-stage trial, whose results were released earlier this month. It showed that half the patients treated with the combination survived advanced melanoma with a common gene mutation called a BRAF mutation nearly three years after the treatment.
Array Biopharma Inc (NASDAQ: ARRY ) shares were halted Wednesday after the Food and Drug Administration approved its drug candidate. What Happened The FDA approved Braftovi in combination with Mektovi ...
- Approval based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival - - BRAFTOVI + MEKTOVI now available for patients with advanced BRAF -mutant melanoma - BOULDER, ...
The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer. The combination therapy, which consists of encorafenib and binimetinib, is approved http://bit.ly/2tNoOQW to treat patients with advanced melanoma associated with a common gene mutation called a BRAF mutation, the FDA said. Shares of Array BioPharma were halted in afternoon trading.
The U.S. Food and Drug Administration said on Wednesday it had approved Array BioPharma Inc's combination treatment for use in patients with the deadliest form of skin cancer. The oral drugs, encorafenib ...
Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
- Median Overall Survival (mOS) was not reached; OS data are fully mature through 12.6 months - - Encore investor webcast today at 10:30 am Eastern Time - BOULDER, Colo. , June 23, 2018 /PRNewswire/ -- Array ...
On June 20, Array BioPharma’s stock price grew 5.2% and reached $19.99 from its close of $19.0 the previous day. On June 20, Array BioPharma hit its 52-week high of $20.18.
Two marijuana companies are among our top stocks to watch today, as Canada has legalized recreational marijuana use nationwide. On Monday the company announced it closed a strategic investment in Choom Holdings to expand its marijuana production. Canopy Growth Corp. (CGC) added $1.22 to $32.05 on 4.4 million shares traded.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
- Encore investor webcast presentation June 23, 2018 - BOULDER, Colo. , June 18, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated safety and efficacy results, ...
Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements. ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 24. Index (PMI) data, output in the Healthcare sector is rising.
Trevena (NASDAQ:TRVN) and Array Biopharma (NASDAQ:ARRY) investors could be celebrating soon enough, should these two drug makers achieve that triumphant FDA approval at the close of a winding biotech road. Between Trevena's opioid asset oliceridine, designed as an intravenous treatment of severe acute pain, and Array's BRAF-mutant melanoma combination therapy candidate encorafenib + binimetinib getting close to final FDA verdicts, two bulls at Cowen are out shedding light on the opportunity ahead. By Cowen's bet, these drug makers are steaming ahead to stamps of FDA approval.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Array BioPharma Inc (NASDAQ:ARRY) with a market-capitalization of US$3.38B, rarely draw their attention. However, generally ignored mid-capsRead More...
-- Combination of encorafenib and binimetinib achieved 33.6 month median overall survival -- -- Data shows limited use of post-trial immunotherapy across treatment groups -- -- Phase 3 COLUMBUS results ...